European medical device maker Ypsomed has launched a new €100m plant manufacturing injection and infusion systems in Schwerin, north eastern Germany to provide extra capacity for future demand.
Ypsomed, based in Burgdorf, Switzerland, constructed the 24,000m2 medical technology plant on a 100,000m2 industrial site in the capital city of the German state of Mecklenburg-Vorpommern.
The firm, which broke ground on the new facility two years ago, is creating 150 local jobs in the unit’s initial five year development phase. Ypsomed expects the workforce total to reach 200 as it utilises the plant’s full production capacity.
Its latest operation was formally opened at a ceremony last month (Aug) attended by the German Health Minister Jens Spahn and Manuela Schwesig, Prime Minister of Mecklenburg-Vorpommern state as well as Ypsomed directors and managers.
Development in Germany follows recent reorganisation and expansion of existing capacity at the company’s Swiss production plants. Space for further growth there is due to be exhausted by 2020.
“Following the full expansion of our Swiss sites, the new production plant will provide us with the necessary capacity expansion to ensure our growth over the next few years,” confirmed Ypsomed’s chief executive officer Simon Michel. Schwerin provided “ideal conditions” including the supply of skilled workers, he added.
Ypsomed’s latest plant comprises a 13,500m2 production area equipped with injection moulding machines, state-of-the-art cleanrooms, printing systems, assembly and packaging machines and quality control section. It also includes a 4,250m2 logistics warehouse and technical maintenance section.
Apart from manufacturing self care medical injection and infusion systems in Germany the firm is due to produce infusion sets for insulin pumps there.
In Switzerland, Ypsomed is relocating 110 posts from its Diabetes Care division and pther business areas from its Burgdorf headquarters site north to its main plant in Solothurn. It is also boosting employment there to handle fresh demand.
In the past three years, it hired 300 more workers in Switzerland at both its sites with 160 located in Solothurn. The firm recently committed to creating another 300 new jobs at both plants over the next three years.
Ypsomed group recorded a net profit of €45.4m on annual turnover valued at €406.6m in the year to 2018.